Early identification of risk factors for refractory secondary hyperparathyroidism in patients with long-term renal replacement therapy

Nephrology Dialysis Transplantation

Volumn 19, Issue 5, 2004, Pages 1168-1173

  Jorna, Francisca H ^a   Tobé, Tom J M ^a   Huisman, Roel M ^a,b   de Jong, Paul E ^a   Plukker, John T M ^a   Stegeman, Coen A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Dialysis Center Groningen   (Netherlands)

Author keywords

Parathyroid hormone; Parathyroidectomy; Phosphorus; Renal replacement therapy

Indexed keywords

ALFACALCIDOL; ALKALINE PHOSPHATASE; ALUMINUM HYDROXIDE; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; DIHYDROTACHYSTEROL; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; SEVELAMER; VITAMIN D;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CALCIUM BLOOD LEVEL; CALCIUM METABOLISM; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; PERITONEAL DIALYSIS; PHOSPHATE BLOOD LEVEL; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RENAL SYSTEM PARAMETERS; RISK FACTOR; SECONDARY HYPERPARATHYROIDISM;

CHILD; FOLLOW-UP STUDIES; HUMANS; HYPERPARATHYROIDISM, SECONDARY; INFANT; KIDNEY DISEASES; MIDDLE AGED; PARATHYROIDECTOMY; RENAL DIALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 2442593784     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh018     Document Type: Article

References (20)

1. Locatelli F, Cannata-Andia JB, Drueke TB et al. Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. Nephrol Dial Transplant 2002; 17: 723-731
2. Malberti F, Marcelli D, Conte F et al. Parathyroidectomy in patients on renal replacement therapy: an epidemiologic study. J Am Soc Nephrol 2001; 12: 1242-1248
3. Decker PA, Cohen EP, Doffek KM et al. Subtotal parathyroidectomy in renal failure: still needed after all these years. World J Surg 2001; 25: 708-712
4. Martinez I, Saracho R, Montenegro J, Llach F. The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis 1997; 29: 496-502
5. Goodman WG. Recent developments in the management of secondary hyperparathyroidism. Kidney Int 2001; 59: 1187-1201
6. Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error, J Am Soc Nephrol 1993; 4: 1205-1213
7. Raman A. The calcium fractions of normal serum. Clin Biochem 1971; 4: 141-146
8. Mizumoto D, Watanabe Y, Fukuzawa Y, Yuzawa Y, Yamazaki C. Identification of risk factors on secondary hyperparathyroidism undergoing long-term haemodialysis with vitamin D3. Nephrol Dial Transplant 1994; 9: 1751-1758
9. Goodman WG, Veldhuis JD, Belin TR et al. Calcium-sensing by parathyroid glands in secondary hyperparathyroidism. J Clin Endocrinol Metab 1998; 83: 2765-2772
10. Slatopolsky E, Brown A, Dusso A. Role of phosphorus in the pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 2001; 37: S54-S57
11. Edwards RM. Disorders of phosphate metabolism in chronic renal disease. Curr Opin Pharmacol 2002; 2: 171-176
12. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617
13. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 2131-2138
14. Rubel JR, Milford EL. The relationship between serum calcium and phosphate levels and cardiac valvular procedures in the hemodialysis population. Am J Kidney Dis 2003; 41: 411-421
15. Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 2000; 35: 1226-1237
16. Chertow GM, Burke SK, Dillon MA, Slatopolsky E. Long-term effects of sevelamer hydrochloride on the calcium × phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 1999; 14: 2907-2914
17. Frazao JM, Martins P, Coburn JW. The calcimimetic agents: perspectives for treatment. Kidney Int Suppl 2002; 61: 149-154
18. Brown AJ, Dusso AS, Slatopolsky E. Vitamin D analogues for secondary hyperparathyroidism. Nephrol Dial Transplant 2002; 17 [Suppl 10]: 10-19
19. Lindberg J, Martin KJ, Gonzalez EA et al. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease. Clin Nephrol 2001; 56: 315-323
20. Teng M, Wolf M, Lowrie E et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-456